Psychiatric Drug Trials Proposed New Biomarker Focus
A new industry roadmap suggests using biological signals to help doctors move away from trial-and-error prescribing.
Updated on Sept. 29, 2026 in Mental Health
Live Poll
Do you support using biological tests to help determine the best psychiatric medication for a patient?
The American College of Neuropsychopharmacology has released a new position paper detailing a shift toward biomarker-guided psychiatric drug trials. This approach could eventually help identify patient subgroups, changing how mental health conditions are treated in the United States.
Why it matters
Current psychiatric treatment often relies on a time-consuming and costly process of trial-and-error prescribing to find effective medications. This roadmap aims to modernize development, potentially lowering costs and improving patient outcomes through more precise, data-driven decisions.
The ACNP Precompetitive Stakeholder Task Force, including experts from UCLA Health and the FDA, published a roadmap in the journal NPP - Digital Psychiatry and Neuroscience. It proposes using measurable signals from blood, brain activity, and wearable devices for drug trials.
The players
American College of Neuropsychopharmacology
A professional society of scientists dedicated to understanding and treating brain and behavior disorders.
UCLA Health
A major academic medical center involved in co-leading the stakeholder task force for this research initiative.
National Institute of Mental Health
The lead federal agency for research on mental disorders that contributed to the task force recommendations.
FDA Office of Neuroscience
The regulatory division overseeing the safety and efficacy of drugs used to treat nervous system disorders.
The details
The task force recommends conducting focused studies that use objective biological markers—such as blood tests, genetic profiles, and electroencephalography—to stratify patients into subgroups. By collecting this data through standardized methods and sharing it within a precompetitive framework, researchers hope to move psychiatry toward a more evidence-based model similar to existing practices in oncology and cardiology.
Timeline
September 18, 2026: UCLA Health released a related news release regarding the task force effort.
September 29, 2026: The American College of Neuropsychopharmacology published the position paper.
Health Landscape
This roadmap marks a deliberate attempt to align psychiatric drug development with the high-precision, biomarker-based models already standard in fields like oncology and cardiology. It represents a significant shift from the historical reliance on subjective symptom observation toward more quantifiable biological indicators.
While these trials are in the early, industry-led planning stages, the shift toward biomarker-guided care may eventually lead to more personalized medication choices that work faster for your specific biology. If you are currently struggling to find an effective treatment, keep this development in mind as a topic to discuss with your doctor in the coming years.
The takeaway
The move toward using blood tests, genetics, and wearables for psychiatric drug trials represents a push for more precise mental health treatment. As this field evolves, track your own symptoms consistently and discuss any new biomarker-related treatment options or diagnostic tests with your physician.
Further reading
For additional context on how researchers track shifts in psychiatric care, explore the Mental Health section.
Source note: This article includes information reported by Psychiatrictimes.
Live Poll
Do you support using biological tests to help determine the best psychiatric medication for a patient?
